コンテンツへスキップ
Merck
  • Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.

Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease.

Liver international : official journal of the International Association for the Study of the Liver (2013-10-11)
Krzysztof Kurek, Dominika M Piotrowska, Patrycja Wiesiołek-Kurek, Bartłomiej Łukaszuk, Adrian Chabowski, Jan Górski, Małgorzata Zendzian-Piotrowska
要旨

Nonalcoholic fatty liver disease (NAFLD) is an insulin resistance-related hepatic disorder which can transform to cirrhosis. Insulin resistance deregulates hepatic lipid metabolism, leading to accumulation of cytotoxic lipids including ceramide and diacylglycerols. Myriocin, obtained from fungi traditionally used in Chinese medicine in an effort to attain eternal youth, is a potent pharmacological inhibitor of ceramide de novo synthesis. We examined whether inhibition of ceramide de novo synthesis with myriocin ameliorate hepatic lipid accumulation and reverse NAFLD. The experiment was carried out on male Wistar rats. The animals were divided into four groups: (i) control group, fed standard rodent diet, (ii) group, fed standard diet also treated with myriocin for 7 days, (iii) group, fed high-fat diet for 5 weeks, (iv) group, fed high-fat diet and treated with myriocin. In liver samples sphingolipids: ceramide, sphingosine and sphingosine-1-phosphatate and neutral lipids, such as diacylglycerols and triacylglycerols were measured. In peripheral blood samples, glucose and insulin levels and aminotransferases activities were measured. High-fat diet feeding caused NAFLD, confirmed by histological assessment, with increased hepatic lipids accumulation and whole-body insulin resistance. After treating with inhibitor of ceramide de novo synthesis, decrease in hepatic ceramide and other toxic lipids were noticed. Moreover, histological analysis of liver samples revealed that inhibition of ceramide de novo synthesis reduced hepatic steatosis. Inhibition of ceramide de novo synthesis reduced hepatic lipid accumulation in rats with NAFLD, this led to amelioration of hepatic steatosis.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
2,6-ジ-tert-ブチル-4-メチルフェノール, ≥99.0% (GC), powder
カタログ番号
容量
在庫状況
単価
数量
Sigma-Aldrich
ブチル化ヒドロキシトルエン, ≥99%, FCC, FG
カタログ番号
容量
在庫状況
単価
数量
USP
ブチル化ヒドロキシトルエン, United States Pharmacopeia (USP) Reference Standard
カタログ番号
容量
在庫状況
単価
数量
Sigma-Aldrich
ペンタデカン酸, 99%
カタログ番号
容量
在庫状況
単価
数量
Sigma-Aldrich
ペンタデカン酸, ~99% (capillary GC)
カタログ番号
容量
在庫状況
単価
数量
Sigma-Aldrich
2,6-ジ-tert-ブチル-4-メチルフェノール, purum, ≥99.0% (GC)
カタログ番号
容量
在庫状況
単価
数量
Supelco
ブチル化ヒドロキシトルエン, Pharmaceutical Secondary Standard; Certified Reference Material
カタログ番号
容量
在庫状況
単価
数量
Sigma-Aldrich
N-Palmitoyl-D-sphingosine, ≥98.0% (TLC)
カタログ番号
容量
在庫状況
単価
数量
Supelco
ペンタデカン酸, analytical standard
カタログ番号
容量
在庫状況
単価
数量
Sigma-Aldrich
2,6-ジ-tert-ブチル-4-メチルフェノール, tested according to Ph. Eur.
カタログ番号
容量
在庫状況
単価
数量